Roivant Sciences Ltd. Common Shares (ROIV) Valuation
Historical valuation analysis based on 500 data points (2024-09-27 to 2026-09-25)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology...
Roivant Sciences Ltd. Common Shares (ROIV) currently trades at a P/S ratio of 1845.28 (range: 94.66–2155.06, 90th percentile — expensive relative to its history).
Roivant Sciences Ltd. Common Shares trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 1845.28 | 94.66 | 1366.95 | 2155.06 | 90th | expensive relative to its history |
Roivant Sciences Ltd. Common Shares (ROIV) Valuation & P/E History
Roivant Sciences Ltd. Common Shares (ROIV) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $35.80 with a market capitalization of $25.9 billion. This page provides historical valuation analysis for ROIV based on 500 data points covering 2024-09-27 to 2026-09-25.. The P/S ratio of 1845.28 compares to a median of 1366.95.
ROIV Valuation Metrics & Historical Range
The valuation table above shows Roivant Sciences Ltd. Common Shares's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ROIV is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ROIV is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Roivant Sciences Ltd. Common Shares.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ROIV Overvalued or Undervalued?
Roivant Sciences Ltd. Common Shares trades well above its own historical valuation range across most metrics. The overall valuation percentile of 90 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ROIV is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ROIV analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ROIV trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.